Tiotropium Respimat inhaler and the risk of death in COPD. - Test2 - elhamkhani - TriplyDB

Tiotropium Respimat inhaler and the risk of death in COPD.

Tiotropium Respimat inhaler and the risk of death in COPD.

http://www.wikidata.org/entity/Q34655749

about

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta 2 -agonists (LABA) for adults with asthma Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma Tiotropium versus placebo for chronic obstructive pulmonary disease Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease Diagnosing COPD: advances in training and practice - a systematic review Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies A rational approach to single, dual and triple therapy in COPD Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data.Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: respiratory review of 2014.Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch Tiotropium in asthma: a systematic review Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.

P2860

Q24186370-F69F8FF1-ED3E-4A53-BC71-7CC24FF0B09D Q24186411-EAC124BA-4C2C-4704-9D35-3D84C8592F3C Q24187031-06D9C9B5-9A65-4382-A75A-CD44619C887E Q24187073-8A117488-457D-4294-BDAD-F93CCCA0D187 Q24187322-6AF4454B-5950-4580-A70D-202EAD295373 Q24187595-34361CE0-06A1-4730-998C-5DBE08936635 Q24194833-1DA1282D-E719-4804-AB5D-574E85B68F75 Q26741051-CDB623C8-0850-4C0A-8057-9466E7884B3E Q26751313-6C72F347-99F1-486F-9C68-5D0B5722B123 Q26769046-3D302F24-DE2C-4EFB-9ED3-11DFE425E814 Q26776477-3A293DCC-1BE7-4F99-9235-DF8225BB76F3 Q26780553-013741CF-5E0E-4B15-BBC1-3DCC9F7A2675 Q26786162-069A96A3-B913-4322-9CE2-3CF7E30465B9 Q26828602-15D28F7D-8336-48FB-9C8E-C3A289B9566E Q27022636-F5DBB22D-9D7A-42C6-AB03-10123E32A1E0 Q27023223-E0C56D17-E7A2-4C1B-ADE8-E73A7BAD7383 Q27348844-75376C89-E6DC-4D58-AA6A-939056A1BFBF Q28067579-9A43F6AA-C8A7-4AA4-9925-EB22A9A66BB8 Q28068078-A369DEF9-11CA-4231-B311-EFF939DFE8BE Q28070274-EABA393D-8AA5-4731-93CA-7597A30D1B00 Q28546584-1092B58C-D076-47FC-B01F-2E46BF8FCB2C Q30620671-5B8F2C51-36B4-4581-8E30-A4D5D7CA1A6C Q30820402-AD5DF6CD-222F-47B1-911A-EE632AC2353E Q30877371-73616D43-62B3-4637-A30F-0077B637FDD9 Q30990525-0A1CA2B6-DCDA-4872-BADA-964F589E79D4 Q33590384-62900575-E376-432C-A101-E98011D40F20 Q33672615-02EF8E87-F584-4FD3-B006-88D2A30D36AE Q34042468-D7AB0646-6E4E-44B2-8BD3-DFBD298518CC Q34440060-66F61DC5-0512-45FA-A993-E4C55E186F16 Q34443454-06FB44E1-60C2-4862-89FC-29C8B6705AC5 Q34550471-9AD6932B-A5B5-4E6C-82DE-C4858EE674AE Q34944616-18412731-94FB-43D1-95A8-69365B1B95F9 Q35112216-F321EB7A-12B0-4CF8-8800-91D136244B60 Q35344118-296C146C-83ED-4D4F-87DD-708DEE031E21 Q35538249-453ABD40-2431-4F7C-895B-284810D05799 Q35675649-1FDC9C48-4C5C-47C9-8449-7F69B84201B1 Q35766346-DF2B62E4-AAB6-4B5D-AC59-EABD90695B3E Q35774959-49B59D35-0A42-476C-8E8E-3E3B4B40941A Q35802628-251BE336-CA7F-482E-881C-E33930AC91AE Q35838660-6A3520FC-4F8A-41B7-87A6-2F4DB1E38762

P2860

Tiotropium Respimat inhaler and the risk of death in COPD.

http://www.wikidata.org/entity/Q34655749

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Tiotropium Respimat inhaler and the risk of death in COPD.

@ast

Tiotropium Respimat inhaler and the risk of death in COPD.

@en

Tiotropium Respimat inhaler and the risk of death in COPD.

@nl

type

label

Tiotropium Respimat inhaler and the risk of death in COPD.

@ast

Tiotropium Respimat inhaler and the risk of death in COPD.

@en

Tiotropium Respimat inhaler and the risk of death in COPD.

@nl

prefLabel

Tiotropium Respimat inhaler and the risk of death in COPD.

@ast

Tiotropium Respimat inhaler and the risk of death in COPD.

@en

Tiotropium Respimat inhaler and the risk of death in COPD.

@nl

P1433

Q34655749-153E6004-3F46-490A-A361-54F1C9599CDD

P1476

Q34655749-10735FB5-CA43-476A-A923-3335B8E07EF0

P2093

Q34655749-18B4DD7C-B37A-4A85-81C1-55CCE007545A

Q34655749-1CF5292B-2210-4343-954E-757D0947787B

Q34655749-4899F8B0-65A7-4E77-B53F-EC63AEC856CF

Q34655749-4B036D27-6428-4A90-A3D0-9468E6EA63B9

Q34655749-5511A796-636A-4301-B5CC-1382EB29F8A7

Q34655749-7FDFE809-7432-4340-9A5A-3E24D97493A9

Q34655749-8E2387A4-7C5D-4B13-BB30-3D95305A76AF

Q34655749-97BDEDC2-6C0B-42D6-BA2E-CCF37D961659

Q34655749-BCB05AE2-D859-4E5B-BBA5-0A6248ADBEE8

Q34655749-D1BB110C-7B19-4ECC-BF96-A4D7E802051A

P304

Q34655749-BB16E01D-BAC5-4500-87B8-15D617C0CF01

P31

Q34655749-C9F204CE-2486-456A-B079-E1067339B15E

P356

Q34655749-829409C8-4579-4181-8258-AB095AAD87B0

P407

Q34655749-FC9149BF-F6CE-4286-9ADE-5696A25A56A3

P433

Q34655749-B99D1ABA-817A-4891-8F42-0940EDA27193

P478

Q34655749-E93ED137-55F3-4ACB-88E7-345533C8F604

P50

Q34655749-5ECC7990-9485-4AF0-A30C-84C669C16AA8

P577

Q34655749-3F6E603E-28AD-4F40-8148-0E4B7CABA5F6

P698

Q34655749-6C8A6D62-E11A-41E8-BF3D-E1257CF18E42

P921

Q34655749-6E614DD5-E101-4111-8B7E-7984D395C73F

P356

P1433

The New England Journal of Medicine

P1476

Tiotropium Respimat inhaler and the risk of death in COPD.

@en

P2093

Bernd Disse

http://www.w3.org/2001/XMLSchema#string

Daniel Cotton

http://www.w3.org/2001/XMLSchema#string

Daniel Dusser

http://www.w3.org/2001/XMLSchema#string

Elizabeth Joseph

http://www.w3.org/2001/XMLSchema#string

Gordon Pledger

http://www.w3.org/2001/XMLSchema#string

Michael Koenen-Bergmann

http://www.w3.org/2001/XMLSchema#string

Peter Calverley

http://www.w3.org/2001/XMLSchema#string

Robert A Wise

http://www.w3.org/2001/XMLSchema#string

Ronald Dahl

http://www.w3.org/2001/XMLSchema#string

Sabine Kattenbeck

http://www.w3.org/2001/XMLSchema#string

P304

1491-1501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1303342

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Anzueto

P577

2013-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23992515

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease